AbbVie Inc. (ABBV) to Issue Quarterly Dividend of $1.73 on May 15th

AbbVie Inc. (NYSE:ABBV) declared a quarterly dividend on Thursday, February 19th. Stockholders of record on Wednesday, April 15th will be paid a dividend of 1.73 per share on Friday, May 15th. This represents a c) annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Wednesday, April 15th.

AbbVie has increased its dividend payment by an average of 0.1%per year over the last three years and has raised its dividend annually for the last 53 consecutive years. AbbVie has a dividend payout ratio of 49.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect AbbVie to earn $13.98 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 49.5%.

AbbVie Stock Up 0.1%

ABBV opened at $208.22 on Monday. The firm has a market cap of $368.16 billion, a price-to-earnings ratio of 88.23, a price-to-earnings-growth ratio of 0.75 and a beta of 0.38. AbbVie has a fifty-two week low of $168.54 and a fifty-two week high of $244.81. The company’s 50-day moving average price is $220.35 and its 200 day moving average price is $224.04.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts anticipate that AbbVie will post 12.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ABBV shares. UBS Group reduced their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. Citigroup decreased their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. William Blair restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Cantor Fitzgerald lowered their price target on shares of AbbVie from $250.00 to $240.00 and set an “overweight” rating on the stock in a report on Wednesday, April 8th. Finally, Morgan Stanley boosted their price target on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $253.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.